Use of brodalumab for the treatment of psoriasis and psoriatic arthritis.
Psoriasis is a chronic immune-mediated disease that affects 2-3% of the population worldwide. Over the past two decades new data on the physiopathology of psoriasis have opened the door for novel therapeutic options. The IL-23-Th17 axis has been shown to play a key role in the inflammatory cascade central to this disease. IL-17 inhibitors are a new group of drugs that have shown excellent clinical effectiveness for the treatment of moderate-to-severe psoriasis in current clinical trials. Brodalumab is an antibody against IL-17 receptor subunit A (IL-17RA). This article reviews the available published data on brodalumab for the treatment of moderate-to-severe psoriasis and psoriatic arthritis.
Baylor University Medical Center, 3900 Junius Street, Suite 125, Dallas, TX 75246, USA.
Dario N
DN
Kivelevitch
Alan
A
Menter
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015535:Arthritis, Psoriatic / Q000276:immunology / Q000628:therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D020381:Interleukin-17 / Q000378:metabolism*; D053759:Interleukin-23 / Q000378:metabolism; D011565:Psoriasis / Q000276:immunology / Q000628:therapy*; D053722:Receptors, Interleukin-17 / Q000276:immunology*; D058504:Th17 Cells / Q000187:drug effects / Q000276:immunology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C109985:IL17RA protein, human; D020381:Interleukin-17; D053759:Interleukin-23; D053722:Receptors, Interleukin-17; C571216:brodalumab
IL-17; anti-IL-17; brodalumab efficacy; monoclonal antibodies; psoriasis; psoriatic arthritis; safety; therapeutics